Meningococcal disease: The organism, clinical presentation, and worldwide epidemiology

Journal of Travel Medicine

Volumn 17, Issue SUPPL. 1, 2010, Pages 3-8

  Al Tawfiq, Jaffar A ^a   Clark, Thomas A ^b   Memish, Ziad A ^c  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; VIRULENCE FACTOR;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL ASSESSMENT; DISEASE CARRIER; EPIDEMIC; HUMAN; INCIDENCE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; VACCINATION;

AFRICA; ASIA; CANADA; COMMUNICABLE DISEASES, EMERGING; ENDEMIC DISEASES; EUROPE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PRIMARY PREVENTION; SAUDI ARABIA; UNITED STATES;

EID: 77956936981     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/j.1708-8305.2010.00448.x     Document Type: Review

References (79)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009 27 (Suppl 2 B51 63.
2. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. J Exp Med 1969 129 : 1367 1384.
3. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007 31 : 3 14.
4. Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 1977 9 : 105 110.
5. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2005 1 11.
6. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. J Exp Med 1969 129 : 1327 1348.
7. Dull PM, Abdelwahab J, Sacchi CT, et al. Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj. JID 2005 191 : 33 39.
8. MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. EID 2006 12 : 950 957.
9. Bilukha OO, Rosenstein N, National Center for Infectious Diseases CfDC, Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid & Mortal Wkly Rep. Recom & Rep 2005 54 : 1 21.
10. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. New Eng J Med 2001 344 : 1378 1388.
11. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998 95 : 3140 3145.
12. Cartwright KA. Early management of meningococcal disease. Infect Dis Clin North Am 1999 13 : 661 684.
13. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. JID 1999 180 : 1894 1901.
14. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981 99 : 540 545.
15. Peltola H. Prophylaxis of bacterial meningitis. Infect Dis Clin North 1999 13 : 685 710.
16. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995 273 : 383 389.
17. Brooks R, Woods CW, Benjamin Jr. DK, Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 2006 43 : 49 54.
18. Memish Z. Meningococcal disease and travel. Clin Infect Dis 2002 34 : 84 90.
19. Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa; has anything changed? Trop Med Int Health 2006 11 : 773 780.
20. Lapeyssonnie L. La méningite cérébrospinale en Afrique. Bull W H O 1963 28 (Suppl 1 100.
21. Molesworth AM, Thomson MC, Connor SJ, et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002 96 : 242 249.
22. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007 44 : 657 663.
23. Djibo S, Nicolas P, Alonso JM, et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003 8 : 1118 1123.
24. Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. JID 2002 185 : 618 626.
25. Koumare B, Ouedraogo-Traore R, Sanou I, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007 25 (Suppl 1 A37 41.
26. Mayer LW, Reeves MW, Al-Hamdan N, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. JID 2002 185 : 1596 1605.
27. Traore Y, Njanpop-Lafourcade BM, Adjogble KL, et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006 43 : 817 822.
28. Ryder C, Beatty D, Heese H. Group B meningococcal infection in children during an epidemic in Cape Town, South Africa. Ann Trop Paediatr 1987 7 : 47 53.
29. von Gottberg A, du Plessis M, Cohen C, et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008 46 : 377 386.
30. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. JID 1998 177 : 497 500.
31. Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain [see comments]. JAMA 1999 281 : 1493 1497.
32. Sacchi CT, Pessoa LL, Ramos SR, et al. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. JCM 1992 30 : 1734 1738.
33. Tsang RS, Squires SG, Zollinger WD, Ashton FE. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis 2002 13 : 391 396.
34. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010 50 : 184 191.
35. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR 2009 58 : 997 1001.
36. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep = Releve des Maladies Transmissibles au Canada 2006 32 : 97 107.
37. Bettinger JA, Scheifele DW, Le Saux N, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009 28 : 220 224.
38. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep 2007 33 : 1 15.
39. Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007 33 : 1 12.
40. Tsang RS, Kiefer L, Law DK, et al. Outbreak of serogroup C meningococcal disease caused by a variant of Neisseria meningitidis serotype 2a ET-15 in a community of men who have sex with men. JCM 2003 41 : 4411 4414.
41. Law DK, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). JCM 2006 44 : 2743 2749.
42. Safadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010 32 : 263 271.
43. Souza de Morais J, Munford RS, Risi JB, et al. Epidemic disease due to serogroup C Neisseria meningitidis in Sao Paulo, Brazil. JID 1974 129 : 568 571.
44. Cruz C, Pavez G, Aguilar E, et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect 1990 105 : 119 126.
45. Sosa J, Llanes R, Guzman D, et al. Typing and susceptibility to penicillin of Neisseria meningitidis isolated from patients in Cuba (1993-1999). Memorias do Instituto Oswaldo Cruz 2001 96 : 523 525.
46. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992 340 : 1074 1078.
47. Dominguez F, Menendez J, Ochoa R. An effective serogroup B meningococcal vaccine.[comment]. Vaccine 2006 24 : 7025 7026.
48. Efron AM, Sorhouet C, Salcedo C, et al. W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. JCM 2009 47 : 1979 1980.
49. Ines Agudelo C, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis 2008 14 : 990 991.
50. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007 31 : 27 36.
51. Ramsay M, Fox A. Invasive Neisseria meningitidis in Europe - 2001: European Union Invasive Bacterial Infections Surveillance Network. 2001.
52. Czumbel I, Jansson A, Celentano LP, Gauci AA. Epidemiology of invasive meningococcal disease (IMD) in Europe, 2007. 2008. Available at http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/eurovaccine/documents/ 0912-eurovaccine-id7-czumbel-inv-meningococcal-disease-europe-2007.pdf. (Accessed 2010 June 15).
53. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001 357 : 195 196.
54. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003 326 : 365 366.
55. Caugant DA, Froholm LO, Bovre K, et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci U S A 1986 83 : 4927 4931.
56. Stuart JM, Cartwright KA, Jones DM, et al. An outbreak of meningococcal disease in Stonehouse: planning and execution of a large-scale survey. Epidemiol & Infect 1987 99 : 579 589.
57. Rouaud P, Perrocheau A, Taha MK, et al. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveill 2006 11 : 178 181.
58. Tapsall J. Annual report of the Australian Meningococcal Surveillance Programme, 2008. Commun Dis Intell 2009 33 : 259 267.
59. Jelfs J, Munro R. Epidemiology of meningococcal disease in Australia. J Paediatr Child Health 2001 37 : S3 S6.
60. Patel MS. Australia's century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust 2007 186 : 136 141.
61. O'Hallahan J, Lennon D, Oster P, et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005 23 : 2197 2201.
62. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009 27 (Suppl 2 B3 B12.
63. Zhang X, Shao Z, Zhu Y, et al. Genetic characteristics of serogroup A meningococci circulating in China, 1956-2005. Clin Microbiol Infect 2008 14 : 555 561.
64. Nair D, Dawar R, Deb M, et al. Outbreak of meningococcal disease in and around New Delhi, India, 2005-2006: a report from a tertiary care hospital. Epidemiol & Infect 2009 137 : 570 576.
65. Shao Z, Li W, Ren J, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 2006 367 : 419 423.
66. Ni JD, Jin YH, Dai B, et al. Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China. Postgrad Med J 2008 84 : 87 92.
67. Shao Z, Zhou H, Gao Y, et al. Neisseria meningitidis serogroup W135, China. Emerg Infect Dis 16 : 348 349.
68. Horino T, Kato T, Sato F, et al. Meningococcemia without meningitis in Japan. Intern Med 2008 47 : 1543 1547.
69. Gurley ES, Hossain MJ, Montgomery SP, et al. Etiologies of bacterial meningitis in Bangladesh: results from a hospital-based study. Am J Trop Med Hyg 2009 81 : 475 483.
70. al-Gahtani YM, el Bushra HE, al-Qarawi SM, et al. Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi Arabia, 1992. Epidemiol Infect 1995 115 : 399 409.
71. Aguilera JF, Perrocheau A, Meffre C, et al. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. EID 2002 8 : 761 767.
72. Moore PS, Harrison LH, Telzak EE, et al. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 1988 260 : 2686 2689.
73. El Bushra HE, Hassan NM, Al-Hamdan NA, et al. Determinants of case fatality rates of meningococcal disease during outbreaks in Makkah, Saudi Arabia, 1987-97. Epidemiol Infect 2000 125 : 555 560.
74. Meningococcal disease, serogroup W135 (update). Wkly Epidemiol Rec 2001 76 : 213 214.
75. Issack MI, Ragavoodoo C. Hajj-related Neisseria meningitidis serogroup W135 in Mauritius. EID 2002 8 : 332 334.
76. Fonkoua MC, Taha MK, Nicolas P, et al. Recent increase in meningitis caused by Neisseria meningitidis serogroups A and W135, Yaounde, Cameroon. EID 2002 8 : 327 329.
77. Hahne SJ, Gray SJ, Jean F, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002 359 : 582 583.
78. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003 36 : 679 683.
79. Soriano-Gabarro M, Rosenstein N, LaForce FM. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. J Health Popul Nutr 2004 22 : 275 285.